SEC Company Response from RVL Pharmaceuticals plc (RVLPQ) (CIK 0001739426) — Jan 6, 2020
RVL Pharmaceuticals plc (RVLPQ) (CIK 0001739426)
Date: Jan. 6, 2020 · CIK: 0001739426 · Accession: 0001104659-20-001502
AI Filing Summary & Sentiment
File numbers found in text: 333-235661
Letter
Re: Osmotica Pharmaceuticals plc (the “Company”) Registration Statement on Form S-1 (File No. 333-235661)
VIA EDGAR
January 6, 2020
Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549
Ladies and Gentlemen:
As representatives of the several underwriters of the Company’s proposed public offering of ordinary shares, we hereby join the Company’s request that the effective date of the above-referenced Registration Statement be accelerated so that the above-referenced Registration Statement will be declared effective at 4:00 p.m. (ET) on January 8, 2020, or as soon thereafter as is practicable.
Pursuant to Rule 460 of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act of 1933, as amended, please be advised that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned advise that they have complied and will continue to comply, and that they have been informed by the participating underwriters and dealers that they have complied with and will continue to comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Remainder of Page Intentionally Left Blank]
Very truly yours,
As Representatives of the several Underwriters
Show Raw Text
CORRESP 1 filename1.htm VIA EDGAR January 6, 2020 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Osmotica Pharmaceuticals plc (the “Company”) Registration Statement on Form S-1 (File No. 333-235661) Ladies and Gentlemen: As representatives of the several underwriters of the Company’s proposed public offering of ordinary shares, we hereby join the Company’s request that the effective date of the above-referenced Registration Statement be accelerated so that the above-referenced Registration Statement will be declared effective at 4:00 p.m. (ET) on January 8, 2020, or as soon thereafter as is practicable. Pursuant to Rule 460 of the General Rules and Regulations of the Securities and Exchange Commission under the Securities Act of 1933, as amended, please be advised that there will be distributed to each underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus. The undersigned advise that they have complied and will continue to comply, and that they have been informed by the participating underwriters and dealers that they have complied with and will continue to comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. [Remainder of Page Intentionally Left Blank] Very truly yours, As Representatives of the several Underwriters Jefferies LLC By: /s/ Kevin Sheridan Name: Kevin Sheridan Title: Joint Global Head of Healthcare Investment Banking SVB LEERINK LLC By: /s/ Byron T. Webster Name: Byron T. Webster Title: Managing Director [Signature Page to Acceleration Request]